{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:50:22Z","timestamp":1791399022884,"version":"4.3.3"},"reference-count":157,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multispecific antibodies have redefined the immunotherapeutic landscape in hematologic malignancies. Bispecific antibodies (BsAbs), which redirect cytotoxic T cells toward malignant targets via dual antigen engagement, are now established components of treatment for diseases such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM). Clinical trials of agents like blinatumomab, glofitamab, mosunetuzumab, and teclistamab have demonstrated deep and durable responses in heavily pretreated populations. Trispecific antibodies (TsAbs), although still investigational, represent the next generation of immune redirection therapies, incorporating additional tumor antigens or co-stimulatory domains (e.g., CD28, 4-1BB) to mitigate antigen escape and enhance T-cell persistence. This review provides a comprehensive evaluation of BsAbs and TsAbs across hematologic malignancies, detailing molecular designs, mechanisms of action, therapeutic indications, resistance pathways, and toxicity profiles including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, and infections. We further discuss strategies to mitigate adverse effects and resistance, such as antigen switching, checkpoint blockade combinations, CELMoDs, and construct optimization. Notably, emerging platforms such as tetrafunctional constructs, checkpoint-integrated multispecifics, and protease-cleavable masking designs are expanding the therapeutic index of these agents. Early clinical evidence also supports the feasibility of applying multispecific antibodies to solid tumors. Finally, we highlight the transformative role of artificial intelligence (AI) and machine learning (ML) in multispecific antibody development, including antigen discovery, biomarker-driven treatment selection, toxicity prediction, and therapeutic optimization. Together, BsAbs and TsAbs illustrate the convergence of molecular precision, clinical innovation, and AI-driven personalization, establishing a new paradigm for immune-based therapy across hematologic and potentially solid tumor malignancies.<\/jats:p>","DOI":"10.3390\/ijms26115319","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:40:32Z","timestamp":1748864432000},"page":"5319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies"],"prefix":"10.3390","volume":"26","author":[{"given":"Behzad","family":"Amoozgar","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayrton","family":"Bangolo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Habibi","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University, New Orleans, LA 70118, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplant and Cellular Therapy, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"ref_1","first-page":"3681","article-title":"T-cell\u2013redirecting bispecific antibodies in multiple myeloma: A revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kordic, A., Phillips, T.J., and Weiss, J. (2025). The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL. Cancers, 17.","DOI":"10.3390\/cancers17071192"},{"key":"ref_3","first-page":"2021-2-4","article-title":"Bispecific antibodies for non-Hodgkin\u2019s lymphomas and multiple myeloma","volume":"10","author":"Chavez","year":"2021","journal-title":"Drugs Context"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-023-00714-7","article-title":"Blinatumomab in Practice","volume":"19","author":"Lantz","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","article-title":"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma","volume":"14","author":"Chakraborty","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1535-7163.MCT-22-0498","article-title":"IMiDs Augment CD3-Bispecific Antibody\u2013Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA Approval Summary: Teclistamab\u2013A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-0716-4558-1_20","article-title":"Optimal Structural Designs of Trispecific Antibodies to Enhance Therapeutic Efficacy in Solid Tumors and Hematological Malignancies","volume":"2930","author":"Qi","year":"2025","journal-title":"Cancer Immunosurveill. Methods Protoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1515\/hsz-2023-0329","article-title":"Better safe than sorry: Dual targeting antibodies for cancer immunotherapy","volume":"405","author":"Schoenfeld","year":"2024","journal-title":"Biol. Chem."},{"key":"ref_11","first-page":"30","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA","volume":"35","author":"Verkleij","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after\u2265 2 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fleury, I., MacDonald, D., Shafey, M., Christofides, A., and Sehn, L.H. (2025). Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. Curr. Oncol., 32.","DOI":"10.20944\/preprints202501.1882.v2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2040620719899897","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.clml.2019.09.082","article-title":"AMG 701, a half-life extended anti-BCMA BiTE\u00ae, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment","volume":"19","author":"Cho","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae(bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: First approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","article-title":"Glofitamab CD20-TCB bispecific antibody","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","article-title":"Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma","volume":"40","author":"Moreau","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/bs.ircmb.2022.04.001","article-title":"Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment","volume":"370","author":"Dunai","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e010140","DOI":"10.1136\/jitc-2024-010140","article-title":"Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imm.13743","article-title":"Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics","volume":"171","author":"Ahmed","year":"2024","journal-title":"Immunology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Thisted, T., Smith, F.D., Jiang, Z.G., Onumajuru, A., Biesova, Z., Kleschenko, Y., Malhotra, K., Saxena, V., Mukherjee, A., and van der Horst, E.H. (2025). Dual Targeting for Enhanced Tumor Immunity: Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation. bioRxiv, bioRxiv:07.647657.","DOI":"10.1101\/2025.04.07.647657"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","article-title":"CD28 co-stimulation: Novel insights and applications in cancer immunotherapy","volume":"24","author":"Lotze","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"In, H., Park, M., Lee, H., and Han, K.H. (2025). Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies, 14.","DOI":"10.3390\/antib14010016"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line\u201430 years later: Its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-24-0384","article-title":"The Fc\u03b3RIIIA (CD16) L48-H\/R Polymorphism Enhances NK Cell\u2013Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing","volume":"13","author":"Maskalenko","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: Trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Compte","year":"2023","journal-title":"Theranostics"},{"key":"ref_36","first-page":"1790","article-title":"A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of b-cell non-Hodgkin lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2024-200666","article-title":"JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models","volume":"144","author":"Fontan","year":"2024","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cao, Z., Osellame, L.D., Allan, L., and Scott, A.M. (2025). Clinical development of tri-specific antibodies for immune-oncology. Expert Opin. Investig. Drugs, Online ahead of print.","DOI":"10.1080\/13543784.2025.2511180"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Horenstein, A.L., Faini, A.C., Morandi, F., Ortolan, E., Storti, P., Giuliani, N., Richardson, P.G., and Malavasi, F. (2025). Monoclonal anti-CD38 therapy in human myeloma: Retrospects and prospects. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1519300"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs. chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/imm.13636","article-title":"Trispecific antibodies for cancer immunotherapy","volume":"169","author":"Yao","year":"2023","journal-title":"Immunology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2023-182150","article-title":"A CD38\/CD28xCD3 trispecific T-cell engager (TCE) as a potentially active agent in multiple myeloma patients relapsed and\/or refractory (RRMM) to anti-CD38 monoclonal antibodies (mAbs)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"key":"ref_46","first-page":"1750","article-title":"Optimized CD19\/CD22\/CD3 antibody","volume":"140","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_47","first-page":"751","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/17474086.2021.1935855","article-title":"CD123-targeted therapy in acute myeloid leukemia","volume":"14","author":"Green","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e007494","DOI":"10.1136\/jitc-2023-007494","article-title":"Asymmetric anti-CLL-1\u00d7 CD3 bispecific antibody, ABL602 2+ 1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Guarnera, L., Bravo-Perez, C., and Visconte, V. (2023). Immunotherapy in acute myeloid leukemia: A literature review of emerging strategies. Bioengineering, 10.","DOI":"10.3390\/bioengineering10101228"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study","volume":"136","author":"Ravandi","year":"2020","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sallman, D.A., Al Malki, M., Asch, A.S., Lee, D.J., Kambhampati, S., Donnellan, W.B., Bradley, T.J., Vyas, P., Jeyakumar, D., and Marcucci, G. (2020). Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.7507"},{"key":"ref_53","first-page":"609","article-title":"An anti-CD3\/anti\u2013CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"22579","DOI":"10.18632\/oncotarget.8022","article-title":"Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells","volume":"7","author":"Roskopf","year":"2016","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.3154","article-title":"The evolving therapy of DLBCL: Bispecific antibodies","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: Clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2024-200369","article-title":"Fixed-Duration Epcoritamab in Combination with Bendamustine+ Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3","volume":"144","author":"Brody","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) who have received \u2265 2 prior lines of therapy: Pivotal results from a phase I\/II study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"ref_65","first-page":"94","article-title":"Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1\/2 Results","volume":"197","author":"Linton","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2022-168904","article-title":"PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell malignancies","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2023-179061","article-title":"A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and\/or refractory B-Cell malignancies","volume":"142","author":"Mazza","year":"2023","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi-and Tri-specific antibodies in non-Hodgkin lymphoma: Current data and perspectives","volume":"14","author":"Dulery","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2024-207532","article-title":"Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19\/20\/22 in B-Cell Malignancies","volume":"144","author":"Vasu","year":"2024","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1007\/s00277-024-06078-z","article-title":"Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: A systematic review and meta-analysis","volume":"103","author":"Qureshi","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"HemaSphere"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e70764","DOI":"10.1002\/cam4.70764","article-title":"Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma","volume":"14","author":"Yan","year":"2025","journal-title":"Cancer Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"van de Donk, N.W., Vega, G., Perrot, A., Anguille, S., Oriol, A., Minnema, M., Kaiser, M.F., Lee, H.C., Garfall, A., and Matous, J.V. (2025, April 05). First-in-Human Study of JNJ-79635322 (JNJ-5322), a Novel, Next-Generation Trispecific Antibody (TsAb), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Initial Phase 1 Results. Available online: https:\/\/meetings.asco.org\/abstracts-presentations\/243590.","DOI":"10.1200\/JCO.2025.43.16_suppl.7505"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Grab, A.L., Kim, P.S., John, L., Bisht, K., Wang, H., Baumann, A., Van de Velde, H., Sarkar, I., Shome, D., and Reichert, P. (2024). Pre-Clinical Assessment of SAR442257, a CD38\/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed\/Refractory Multiple Myeloma. Cells, 13.","DOI":"10.3390\/cells13100879"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"},{"key":"ref_80","first-page":"1522","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/1566524023666230622151034","article-title":"Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A review","volume":"24","author":"Sangwan","year":"2024","journal-title":"Curr. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2024-204614","article-title":"First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed\/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma","volume":"144","author":"Schjesvold","year":"2024","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Nolan-Stevaux, O., and Smith, R. (2024). Logic-gated and contextual control of immunotherapy for solid tumors: Contrasting multi-specific T cell engagers and CAR-T cell therapies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1490911"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Locke, F.L., Mahmoudjafari, Z., Kebriaei, P., Gardner, R.A., Frigault, M.J., Frey, N., Komanduri, K.V., Perales, M.A., and Nikiforow, S. (2025). Awakening from REMS: ASTCT 80\/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transplant. Cell. Ther., in press.","DOI":"10.1016\/j.jtct.2025.02.009"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Boutin, L., Barjon, C., Lafrance, L., Senechal, E., Bourges, D., Vigne, E., and Scotet, E. (2023). Targeting human \u03b3\u03b4 T cells as a potent and safe alternative to pan-T cells bispecific cell engagers. bioRxiv, bioRxiv:10.548307.","DOI":"10.1101\/2023.07.10.548307"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical Pharmacology of Cytokine Release Syndrome with T-Cell\u2013Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1182\/blood-2024-199658","article-title":"Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)","volume":"144","author":"Leidy","year":"2024","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Beltran, H., Johnson, M.L., Jain, P., Schenk, E.L., Sanborn, R.E., Thompson, J.R., Dowlati, A., Mamdani, H., Aggarwal, R.R., and Anand, B.S. (2024). Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). J. Clin. Oncol., 42.","DOI":"10.1200\/JCO.2024.42.16_suppl.8090"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"van de Donk, N.W., Moreau, P., Garfall, A.L., Bhutani, M., Oriol, A., Nooka, A.K., Martin, T.G., Rosi\u00f1ol, L., Mateos, M.V., and Bahlis, N.J. (2023). Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol., 41.","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2024-194333","article-title":"Fixed-duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-year Follow-Up From a Pivotal Phase II Study","volume":"144","author":"Dickinson","year":"2024","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/10428194.2024.2426052","article-title":"Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: Clinical vignettes","volume":"66","author":"Paul","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Gao, W., Yu, J., Sun, Y., Song, Z., Liu, X., Han, X., Li, L., Qiu, L., Zhou, S., and Qian, Z. (2025). Adverse events in the nervous system associated with blinatumomab: A real-world study. BMC Med., 23.","DOI":"10.1186\/s12916-025-03913-6"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2023.283931","article-title":"Talquetamab in multiple myeloma","volume":"109","author":"Liu","year":"2023","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Sanz","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_100","unstructured":"Carrara, S.C. (2023). Generation of Multispecific Antibodies with Immune Cell Modulating Functions. [Ph.D. Thesis, Technische Universit\u00e4t Darmstadt]."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Li, H., Zhao, L., Sun, Z., Yao, Y., Li, L., Wang, J., Hua, T., Ji, S., Wang, S., and Cheng, H. (2022). Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1019548"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2023-180421","article-title":"Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1538-7445.AM2025-2140","article-title":"Beyond antibodies and CAR-T: CC312, a first-in-class, anti-CD19, anti-CD3, anti-CD28 trispecific antibody in treatment with relapsed and\/or refractory B-cell malignancies","volume":"85","author":"Huang","year":"2025","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1158\/1538-7445.AM2025-3694","article-title":"Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients","volume":"85","author":"Menon","year":"2025","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"LB128","DOI":"10.1158\/1538-7445.AM2024-LB128","article-title":"Abstract LB128: A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma","volume":"84","author":"Tan","year":"2024","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1158\/1538-7445.AM2025-3406","article-title":"GPRC5D multispecific antibodies with potent anti-tumor activity against multiple myeloma","volume":"85","author":"Roth","year":"2025","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Bangolo, A., Amoozgar, B., Mansour, C., Zhang, L., Gill, S., Ip, A., and Cho, C. (2025). Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17020282"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1182\/blood-2024-202561","article-title":"Efficacy and Safety of Mosunetuzumab in Relapsed\/Refractory Non-Hodgkin Lymphoma: A Systematic Review","volume":"144","author":"Elemian","year":"2024","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1182\/blood-2024-199423","article-title":"MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and\/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase I, First-in-Human, Open-Label, Dose Escalation Study","volume":"144","author":"An","year":"2024","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/17474086.2024.2357274","article-title":"Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: Are we ready for this?","volume":"17","author":"Martino","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-024-01091-x","article-title":"Improving outcomes with anti-BCMA bispecific antibodies with attention to infection","volume":"14","author":"Yee","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.19668","article-title":"Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies","volume":"205","author":"Rafei","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Fu, B., Liu, R., Gao, G., Lin, Z., and He, A. (2024). Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1433774"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA-or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2016","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1007\/s00262-023-03559-4","article-title":"Beyond BCMA, why GPRC5D could be the right way: Treatment strategies with immunotherapy at relapse after anti-BCMA agents","volume":"72","author":"Galimberti","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Staehr","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood-2022-167602","article-title":"Role of TNFRSF17 and GPRC5D structural and point mutations in resistance to targeted immunotherapies in multiple myeloma (MM)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-024-02000-1","article-title":"PD-1 and LAG-3: Synergistic fostering of T cell exhaustion","volume":"9","author":"Hofmann","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Lichtenegger, F.S., Rothe, M., Schnorfeil, F.M., Deiser, K., Krupka, C., Augsberger, C., Schl\u00fcter, M., Neitz, J., and Subklewe, M. (2018). Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00385"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/S2152-2650(24)01666-5","article-title":"MM-336 Long-Term Follow-Up from the Phase 1\/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"24","author":"Garfall","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: A meta-analysis","volume":"20","author":"Ludwig","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_131","first-page":"2456","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-023-01461-1","article-title":"Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: Latest updates from 2022 ASH Annual Meeting","volume":"16","author":"Xia","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Falchi, L., Carlo-Stella, C., Morschhauser, F., Hutchings, M., Bachy, E., Cartron, G., Khan, C., Tani, M., Martinez-Lopez, J., and Bartlett, N.L. (2023). Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study. J. Clin. Oncol., 41.","DOI":"10.1200\/JCO.2023.41.16_suppl.7550"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.3390\/jcm12216737","article-title":"T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma\u2014An Update","volume":"12","author":"Balendran","year":"2023","journal-title":"J. Clin. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1084\/jem.20121416","article-title":"PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis","volume":"210","author":"Zinselmeyer","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic antitumor activity of alnuctamab (ALNUC.; BMS-986349; CC-93269), a BCMA 2+ 1 T cell engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Haber, L., Olson, K., Kelly, M.P., Crawford, A., DiLillo, D.J., Tavar\u00e9, R., Ullman, E., Mao, S., Canova, L., and Sineshchekova, O. (2021). Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93842-0"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14712598.2024.2404079","article-title":"Mosunetuzumab for the treatment of follicular lymphoma","volume":"24","author":"Labanca","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Sun, L., and Romancik, J.T. (2025). The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma. J. Pers. Med., 15.","DOI":"10.3390\/jpm15020051"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/ejh.14405","article-title":"Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies","volume":"114","author":"Bruzzese","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_141","first-page":"265","article-title":"Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies","volume":"48","author":"Peter","year":"2025","journal-title":"Oncol. Res. Treat."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMc2211969","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Cliff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/10600280241271192","article-title":"Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"59","author":"Shaver","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_144","first-page":"3381","article-title":"A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Carrara, S.C., Harwardt, J., Grzeschik, J., Hock, B., and Kolmar, H. (2022). TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1051875"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"207ra144","DOI":"10.1126\/scitranslmed.3006682","article-title":"Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index","volume":"5","author":"Desnoyers","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.25245","article-title":"Overlapping and distinct role of CXCR7-SDF-1\/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas","volume":"127","author":"Grymula","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_149","unstructured":"FDAU (2025, April 05). FDA Grants Accelerated Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer. Available online: https:\/\/www.lungcancerstoday.com\/post\/fda-grants-accelerated-approval-to-tarlatamab-dlle-for-extensive-stage-sclc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1158\/1078-0432.CCR-17-0126","article-title":"A rationally designed fully human EGFRvIII: CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma","volume":"24","author":"Gedeon","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2023.03.046","article-title":"Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity","volume":"357","author":"Leitao","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Li, D., Cheng, P., Wang, J., Qiu, X., Zhang, X., Xu, L., Liu, Y., and Qin, S. (2019). IRF6 is directly regulated by ZEB1 and ELF3, and predicts a favorable prognosis in gastric cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00220"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Marinov, T.M., Wasdin, P.T., Jordaan, G., Janke, A.K., Abu-Shmais, A.A., and Georgiev, I.S. (2025). An expandable synthetic library of human paired antibody sequences. PLOS Comput. Biol., 21.","DOI":"10.1371\/journal.pcbi.1012932"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Prelaj, A., Galli, E.G., Miskovic, V., Pesenti, M., Viscardi, G., Pedica, B., Mazzeo, L., Bottiglieri, A., Provenzano, L., and Spagnoletti, A. (2023). Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1078822"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Tran, K.A., Addala, V., Koufariotis, L.T., Zhang, J., Wood, S., Leonard, C., Hoeijmakers, L.L., Blank, C.U., Crispin-Ortuzar, M., and Williams, E.D. (2025). Explainable machine learning identifies features and thresholds predictive of immunotherapy response. bioRxiv, bioRxiv:23.643560.","DOI":"10.1101\/2025.03.23.643560"},{"key":"ref_157","unstructured":"BioCopy (2025, April 27). BioCopy Chooses Genedata for AI-Powered Multispecific Antibody Development. Available online: https:\/\/www.genedata.com\/company\/news\/details\/press-release\/biocopy-advances-ai-driven-antibody-discovery."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:45:09Z","timestamp":1760031909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":157,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115319"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115319","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}